REG - Hikma Pharmaceutical - Block listing Interim Review

Hikma PharmaceuticalsAnnouncement

14/04/2020 14:35

RNS Number : 6144J
  
Hikma Pharmaceuticals Plc
  
14 April 2020
  
 

Hikma Pharmaceuticals PLC
 
 
Block Listing Six Monthly Return
 
Date: 14 April 2020
 



Name of applicant:


Hikma Pharmaceuticals PLC




Name of scheme:


Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")
 




Period of return


From:


1 October 2019


To:


31 March 2020




Balance of unallotted securities under scheme(s) from previous return:


SOP: 792,700 ordinary shares of 10 pence




Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


SOP: 0 ordinary shares of 10 pence




Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


SOP: 0 ordinary shares of 10 pence 




Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


SOP: 792,700 ordinary shares of 10 pence










 



Name of contact:


Peter Speirs




Telephone number of contact:


0207 399 2772



 
 
Block Listing Six Monthly Return
 
Date: 14 April 2020
 



Name of applicant:


Hikma Pharmaceuticals PLC




Name of scheme:


Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")




Period of return


From:


1 October 2019


To:


31 March 2020




Balance of unallotted securities under scheme(s) from previous return:


LTIP: 102,714 ordinary shares of 10 pence 
 




Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


LTIP: 0 ordinary shares of 10 pence 




Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


LTIP: 15,014 ordinary shares of 10 pence




Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


LTIP: 87,700 ordinary shares of 10 pence 










 



Name of contact:


Peter Speirs




Telephone number of contact:


0207 399 2772



 
Block Listing Six Monthly Return
 
Date: 14 April 2020
 



Name of applicant:


Hikma Pharmaceuticals PLC




Name of scheme:


Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")




Period of return


From:


1 October 2019


To:


31 March 2020




Balance of unallotted securities under scheme(s) from previous return:


MIP: 770,393 ordinary shares of 10 pence




Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


MIP: 1,000,000 ordinary shares of 10 pence




Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


MIP: 8,391 ordinary shares of 10 pence




Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


MIP: 1,519,989 ordinary shares of 10 pence










 



Name of contact:


Peter Speirs




Telephone number of contact:


0207 399 2772



 
Block Listing Six Monthly Return
 
Date: 14 April 2020
 



Name of applicant:


Hikma Pharmaceuticals PLC




Name of scheme:


Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")




Period of return


From:


1 October 2019


To:


31 March 2020




Balance of unallotted securities under scheme(s) from previous return:


EIP: 1,541,128 ordinary shares of 10 pence




Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


EIP: 0 ordinary shares of 10 pence 




Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


EIP:  8,742 ordinary shares of 10 pence




Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


EIP: 1,102,558 ordinary shares of 10 pence










 



Name of contact:


Peter Speirs




Telephone number of contact:


0207 399 2772



 
LEI: 549300BNS685UXH4JI75
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
BLRGPUBPCUPUGWC